Nexavar (sorafenib) tablet is an anticancer medicine for the treatment of patients with unresectable HCC.
Stivarga is an inhibitor of multiple kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis and maintenance of the tumor microenvironment.
Bayer HealthCare Pharmaceuticals US Medical Affairs MD, vice president and head Pamela Cyrus said, "There is an unmet need for HCC patients whose disease has progressed after treatment with sorafenib, the only oral systemic therapy shown to improve overall survival in patients with unresectable HCC."